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Microspheres refer to the micro-particulate polymer based drug delivery system with
an average particle size larger than 1 µm. Microsphere carrier systems made from natu-
rally occurring biodegradable polymers have attracted considerable attention for several
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An investigation into the suitability of mucuna gum mi-
crospheres for oral delivery of glibenclamide is presented.
Mucuna gum microspheres were formulated under dif-
ferent conditions of polymer concentration and crosslink-
ing time at constant speed. The formulated microspheres
were thereafter loaded with glibenclamide by the remote
loading process. The microspheres were evaluated accord-
ing to particle size, yield, loading efficiency and swelling.
In vitro release of glibenclamide from the microspheres
was studied in simulated intestinal fluid (SIF, pH 7.4). The
release data was fitted into two release models to inves-
tigate the mechanism of glibenclamide release from the mic-
rospheres. All the microspheres showed good swelling
characteristics in distilled water. The investigation revealed
that the microspheres produced with 5% (m/V) mucuna
gum with a crosslinking time of 5 h had the optimum
prolonged release pattern. The microspheres produced
using 10% (m/V) mucuna gum with a crosslinking time
of 1 h had the highest delayed release of the incorpo-
rated drug, whereas those without crosslinking had the
fastest release. The Ritger-Peppas case I transport model
appeared to have adequately described the release pro-
cess as about 54% of the batches of microspheres conform-
ed to this model. This implies that a formulation of gli-
benclamide-loaded mucuna gum microspheres is likely
to offer a reliable means of delivering glibenclamide by
the oral route.
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years (1). They have been formulated as mucoadhesive particles or tablets (1–3). There
has been adequate coverage of the microspheres drug delivery system (4, 5). Polymeric
microparticles represent an interesting drug delivery strategy. They shield the encapsu-
lated drug from the external harsh conditions, prolong drug release and may favour up-
take by intestinal cells (6). Many polymers have been used in the formulation of micro-
spheres (7). Biodegradable microspheres break down completely into harmless metabolites
that are easily eliminated through natural body functions. Polymers such as chitosan,
gelatin, polylactic acids and their derivatives have all been extensively studied for their
ability to form microspheres (4, 8, 9).
The polymer proposed in this work (mucuna gum) is a biodegradable polymer. It
was obtained from the plant Mucuna flagillepes (Papillionaceae). It is extracted from the
cotyledons. Mucuna gum is amorphous, insoluble in alcohol and swells to a viscous
mass in water. Mucuna gum is edible and no adverse toxicological effect of the gum has
been reported. It contains D-galactose as the major monosaccharide with the presence of
D-mannose and D-glucose and has been evaluated for use as a food additive (10). In the
pharmaceutical arena, mucuna gum has been shown to be a good suspending agent and
stabilizer in suspensions and emulsions, a good binder in compressed tablets and a good
motif for bioadhesive drug delivery (11–14). The film properties of mucuna gum have
been studied as well (15). Glibenclamide, a second generation sulphonylurea is an orally
bioavailable hypoglycaemic agent used in the management of type II diabetes. The ob-
jectives of this study were to formulate mucuna gum microspheres containing gliben-
clamide, characterize the mucuna gum microsphere delivery systems, and evaluate the
in vitro release characteristics of glibenclamide from such a delivery system.
EXPERIMENTAL
Materials
Materials used include glibenclamide (Pfizer, Nigeria), gelatin, glutaraldehyde and
sodium hydroxide (Merck, Germany) and olive oil (B.P. grade). Other reagents and sol-
vents were of analytical grade and were used without further purification. Mucuna seeds
were locally acquired from Nsukka market.
Methods
Extraction of mucuna gum. – Mucuna seeds were roasted at 70 °C for 10 min to make
the shell brittle. The seeds were then dehusked and the cotyledons were autoclaved in a
1% (m/V) solution of sodium metabisulphite at 121 °C for 15 min. This helps inactivate
the enzymes usually present and also reduces darkening. The cotyledons were then air-
-dried, pulverized in a hammer mill and the flour obtained was soaked in a solution of
1% (m/V) sodium metabisulphite for 24 h and thereafter passed through a muslin cloth.
The resultant filtrate was desolvated with acetone. This product of desolvation (mucuna
gum) was dried in a hot air oven (Model OV110, Gallenkamp, Germany) and then pul-
verized.
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Preparation of microspheres and characterization
Mucuna gum microspheres. – A 50-mL volume of a 5% (m/V) dispersion of the poly-
mer in distilled water was prepared and added dropwise to a beaker containing 50 mL
of olive oil on a stirrer at a speed of 5000 rpm. It was stirred for 30 min at a temperature
of 40 °C. A 15-mL volume of acetone was then added and the mixture was further stirred
for 30 min. The microspheres were then crosslinked with 1 mL of a 4% (V/V) glutar-
aldehyde solution in acetone/0.01 mol L–1 HCl solution (7:3) for a pre-determined time.
The mixture was then centrifuged at a speed of 5000 rpm for 5 min and the microspheres
were recovered. The resulting microspheres were thereafter washed with acetone and
dried at 28 °C. Other batches were similarly prepared. Table I shows the formulation va-
riables.
Gelatin microspheres. – A 50-mL volume of a 5% (m/V) gelatin dispersion was pre-
pared, pre-heated to 40 °C and added dropwise to 50 mL of olive oil at a temperature of
40 °C and stirred at a speed of 5000 rpm for 30 min. Acetone was added as above and a 1
mL volume of glutaraldehyde solution was also added and stirring continued for 1 h.
The microspheres were recovered after centrifugation at a speed of 5000 rpm for 5 min.
Acetone was used to wash the microspheres and then, they were dried at 28 °C.
Particle size determination and swelling studies. – A 5 mg quantity of the microspheres
was placed inside the ring of an internally calibrated microscopic slide (Objective Mi-
crometer, Olympus KS Japan) and a drop of glycerol was added. The slide was covered
with a cover slip and viewed under a binocular microscope at a magnification of X100.
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MGF-0 5.0 0 76.8 6.5 ± 0.9 7.88 ± 1.21 78.8 ± 2.1 12.59 ± 7.12
MGF-1 5.0 1 88.0 5.4 ± 1.2 8.74 ± 2.13 87.4 ± 1.9 17.32 ± 8.20
MGF-3 5.0 3 75.6 2.9 ± 1.2 9.96 ± 1.01 98.4 ± 3.2 6.25 ± 1.89
MGF-5 5.0 5 79.6 5.4 ± 1.1 8.42 ± 1.42 84.2 ± 2.3 15.22 ± 5.99
MGS-0 7.5 0 57.3 5.0 ± 0.9 7.08 ± 2.34 70.8 ± 1.7 42.75 ± 9.15
MGS-1 7.5 1 56.0 4.6 ± 1.1 6.16 ± 3.11 61.6 ± 2.1 22.57 ± 9.17
MGS-3 7.5 3 90.7 4.5 ± 0.8 9.90 ± 0.97 99.0 ± 0.2 32.41 ± 10.43
MGS-5 7.5 5 48.5 6.7 ± 1.3 8.58 ± 1.32 85.8 ± 2.5 13.75 ± 8.82
MGT-0 10.0 0 83.2 5.5 ± 0.8 8.12 ± 0.96 81.2 ± 1.5 16.25 ± 9.16
MGT-1 10.0 1 61.8 5.4 ± 1.1 9.84 ± 0.76 98.4 ± 0.2 8.75 ± 3.39
MGT-3 10.0 3 76.4 4.4 ± 0.9 9.94 ± 0.52 99.4 ± 1.1 13.67 ± 9.82
MGT-5 10.0 5 89.2 4.7 ± 1.1 4.56 ± 2.83 45.6 ± 4.7 11.28 ± 5.46
Gelatin 5.0 1 78.4 4.5 ± 1.2 9.00 ± 1.06 90.0 ± 2.6 11.52 ± 7.96
a Mean ± SD, b n = 5, c n = 3, d n = 50.
Swelling experiments were repeated five times and the swelling factors were calcu-
lated after 60 min swelling.
Drug loading. – A 1000-mg quantity of dried microspheres from each batch was incu-
bated with a solution of glibenclamide [1% (m/V) in 0.1 mol L–1 sodium hydroxide] in
an incubator for 6 h at a temperature of 37 °C. The microspheres were removed and dri-
ed at room temperature.
Preparation of simulated intestinal fluid (SIF, pH 7.4). – SIF (pH 7.4) without pepsin
was prepared following the USP standard (16) from monobasic potassium phosphate.
Loading efficiency. – Each 50 mg of the drug loaded microspheres was put in a 25-mL
volumetric flask, 0.1 mol L–1 sodium hydroxide solution was added to the mark and the
content was allowed to hydrate for 24 h at 28 °C. The solution was filtered, appropri-
ately diluted and then analyzed for glibenclamide content spectrophotometrically (UV-
-VIS Spectrophotometer, Milton Roy, USA) at 226 nm, which was repeated three times
for each batch. This was used to calculate the absolute drug content of the various mic-
rospheres. Beer’s plot for glibenclamide in SIF (pH 7.4) was made at a wavelength of 215
nm and subsequently used for drug release studies.
In vitro release of glibenclamide. – The magnetic stirrer hot plate assembly was used.
A 250-mL volume of SIF (pH 7.4) consisting of the release medium was placed in a 500-
-mL beaker containing a magnetic stirring rod. This was maintained at 37 ± 1 °C with
the aid of a thermoregulated hot plate. In each case, 50 mg of drug loaded microspheres
was placed in a smaller beaker whose bottom was opened and to which, a mesh of aper-
ture size of not greater than 1 mm was attached. This was immersed in the dissolution
medium under agitation of 100 rpm provided by the magnetic stirrer. Ten millilitre sam-
ples were withdrawn and filtered at pre-determined time intervals from the dissolution
medium outside the smaller beaker containing the microspheres. For each sample with-
drawn, an equivalent volume (10 mL) of SIF maintained at the same temperature was
added to the contents of the dissolution medium to maintain sink conditions throughout
the release period. The samples were thereafter analyzed spectrophotometrically at 215 nm.
Two measurements were made for each batch of microspheres.
Release kinetics and mechanism
Higuchi’s square root model (17) primarily describes drug release from a heteroge-
neous matrix where the drug is dispersed uniformly. It aims to describe the drug release
by a combination of drug dissolution and diffusion out of the hydrated or solvated poly-
mer matrix:
F = kH t
where F is the percentage of drug released at time t, while kH is the Higuchi release rate
constant. A plot of F against t1/2 gives a straight line if the process is diffusion controlled.
Ritger-Peppas model (18) is often applied to describe drug release from matrix sys-
tems of various geometries by using a simple exponential relationship:
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where Mt/Ma denotes the fraction of drug released at time t. kRP is the Ritger-Peppas re-
lease rate constant characteristic of the controlled release device and n is the diffusional
exponent, indicative of the mechanism of drug release. In spherical matrices, if n £ 0.43,
a Fickian diffusion (case I), 0.43 £ n  0.85, a non-Fickian transport and n  0.85, a case II
transport (zero-order) drug release mechanism dominates.
RESULTS AND DISCUSSION
The particle size distribution of the microspheres is presented in Table I. The mean
particle size (n = 50) of the microspheres ranged from 6.25 ± 1.89 to 42.75 ± 9.15 mm.
Microspheres formulated with 5.0% (m/V) of mucuna gum and crosslinked for 3 h had
the smallest particle size while microspheres formulated with 7.5% (m/V) of mucuna
gum without crosslinking possessed the largest mean particle size. Viewed under a mi-
croscope, the microspheres had a spherical appearance except for some batches that ap-
peared to have some degree of hydration, especially those prepared with 7.5% (m/V)
mucuna gum. The sizes were all within the lower micrometer range, indicating that the
production process was able to achieve the intended end point. There was no direct cor-
relation between the microsphere size and the crosslinking time. It appeared that the av-
erage size of the microspheres increased with an increase in mucuna gum concentration,
consistent with the earlier report (19). However, the microspheres formulated with 7.5%
(m/V) mucuna gum had a larger size than other microspheres, especially the uncross-
linked microspheres and microspheres crosslinked for 1 h and 5 h because of the partial
hydration mentioned above. These microspheres had particle sizes of 42.75 ± 9.15 µm,
22.57 ± 9.17 µm and 32.41 ± 10.43 µm respectively. Other batches of microspheres had
sizes that were not significantly different from the size of gelatin microspheres, except
those prepared with 5.0% (m/V) mucuna gum with 3 h crosslinking and 10.0% (m/V)
mucuna gum with 1 h crosslinking. Particle size of microparticles/microspheres is a very
important parameter, since it affects drug release and pharmacokinetics (20). For micro-
spheres engineered for parenteral administration, large particles will find it difficult to
pass through the syringe. However, the microspheres evaluated in this study are intend-
ed for oral administration and particle size will influence only the rate of drug release
and subsequent pharmacokinetics.
Results presented in Table I show no evidence of correlation between the mass of
polymer introduced during formulation of microspheres and the microsphere yield (as
well as percentage yield). In all cases, the yield was lower than 100%, both for mucuna
gum alone and gelatin (yield 78%). Particularly noteworthy are the batches that had yields
below 60%. This occurred in microspheres prepared with 7.5% (m/V) of mucuna gum,
except MGS-3. The reason for their low yield could not be explained.
The microspheres swelled to between two and five times their original volume, with
the mircospheres prepared with 7.5% (m/V) mucuna gum and crosslinked for 5 h pro-
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ducing the highest swelling factor, while microspheres prepared with 5.0% (m/V) mu-
cuna gum with 3 h crosslinking produced the lowest swelling factor. In comparison with
the swelling of gelatin microspheres, all the batches exhibited a good swelling profile ex-
cept those prepared with 5.0% (m/V) mucuna gum with 3 h crosslinking. However, the
results show that microspheres crosslinked for 3 h had almost the lowest swelling factor
in the batches. This may be the optimum crosslinking time to produce microspheres for
the sustained release dosage form.
Table I shows that all the microspheres prepared with mucuna gum showed loading
efficiencies not significantly different from microspheres prepared with gelatin, except
microspheres prepared with 5.0% (m/V) and 7.5% (m/V) mucuna gum without cross-
linking and 10.0% (m/V) mucuna gum with crosslinking for 5 h. The batch containing
gelatin as the polymer (standard) had a drug content of 9.00 mg per 100 mg microsphe-
res. Compared with the drug load of gelatin microspheres (90.0 ± 2.6%), the microsphe-
res formulated with 5.0 and 7.5% (m/V) mucuna gum and crosslinked for 3 h [MGF-3
(98.4 ± 3.2%) and MGS-3 (99.0 ± 0.2%), respectively] and microspheres formulated with
10.0% (m/V) of mucuna gum and crosslinked for 1 and 3 h [MGT-1 (98.4 ± 0.2%) and
MGT-3 (99.4 ± 1.1%)] had significantly higher mean loading efficiencies (p < 0.05, n = 3).
This shows the effectiveness of mucuna gum in preparation of microspheres. Since there
was no direct relationship between swelling and crosslinking time, the loading efficien-
cies were not directly related to the crosslinking time except for 3 h crosslinking. Micro-
spheres formulated and crosslinked for 3 h had higher mean drug contents and thus
higher loading efficiencies at all levels of mucuna gum compared to the drug content of
gelatin microspheres (Table I). This was the optimum crosslinking time for the mucuna
gum microspheres using glutaraldehyde. The microspheres showed lower swelling than
the other batches. Higher degree of swelling weakens secondary bonds in polymers and,
thus, the lower degree of swelling in 3 h crosslinked microspheres may have resulted in
stronger attachment of the drug within the mucuna matrix. This is because the drug
loading process adopted was remote loading where the matrix is allowed to imbibe the
drug from a solution. In all, the remote loading process could be used in formulating
mucuna gum microspheres containing glibenclamide. This dosage form would produce
an appropriate controlled glibenclamide delivery system that gradually degrades in the
body.
Release of glibenclamide in SIF from the various batches of microspheres is graphi-
cally represented in Figs. 1a-c, where the percentage amount released is plotted against
time. There was a sustained release of the drug in most of the microspheres. However,
there was an initial burst effect in almost all the microspheres except the microspheres
formulated with 5.0% (m/V) of mucuna gum without crosslinking and that crosslinked
for 3 h, microspheres prepared with 7.5% (m/V) of mucuna gum without crosslinking
and microspheres prepared with 10.0% (m/V) mucuna gum with 1 h crosslinking. This
is common in microspheres, especially those formulated by the remote loading process.
Burst release resulting in biphasic release pattern may be utilized in therapeutic design
of dosage forms. It occurs even in microparticles prepared using other established poly-
mers such as poly(D,L-lactide-co-glycolide) (21, 22). There may be a lot of peripheral at-
tachment of the drug as a result of expulsion during microsphere drying (elastic contrac-
tion as seen in gels) or drug migration as a result of solvent drag during drying. In this
case, however, this may be an advantage because it would lead to a high initial blood
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concentration of the drug and a gradual release of the remaining drug. In diabetes man-
agement, the objective is always to lower the blood sugar level and maintain it at a par-
ticular level. This is possible if a bolus dose of the antidiabetic is administered. The
bolus dose, when required, will be provided by the initial burst as seen in some of the
microsphere formulations in Fig. 1a, and microspheres prepared with 10.0% (m/V) of
mucuna gum and crosslinked for 3 and 5 h (Fig. 1c). Microsphere formulations contain-
ing 10.0% (m/V) mucuna gum without crosslinking or crosslinked for 1 h would not be
appropriate for providing initial high blood concentration of gibenclamide as the formu-
lation containing 10.0% (m/V) mucuna gum without crosslinking emptied all the drug
just after about 1 h, while microspheres prepared with 10.0% (m/V) mucuna gum and
crosslinked for 1 h delayed the release of the incorporated drug for 2.5 h. Microspheres
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Fig. 1. Release profile of glibenclamide from micro-
spheres formulated with: a) 5% (m/V) of mucuna
gum:  MGF-0,  MGF-1,  MGF-3,  MGF-5,
 gelatin; b) 7.5% (m/V) of mucuna gum: MGS-
-0,  MGS-1,  MGS-3,  MGS-5,  gelatin; c)
10% (m/V) mucuna gum:  MGT-0,  MGT-1, 
MGT-3,  MGT-5, gelatin. Each data point re-
presents mean ± SD, n = 3.
prepared with 5.0 or 7.5% (m/V) mucuna gum and crosslinked for 1 and 5 h, and those
prepared with 10.0% (m/V) mucuna gum and crosslinked for 3 and 5 h had the tenden-
cy to fully sustain the release of glibenclamide. All these microsphere formulations need
to be fully optimized using laboratory animals. Mucuna gum possesses bioadhesive pro-
perties (11). This is an added advantage since the transit time of the dosage form would
be prolonged in the gastrointestinal tract for maximum absorption of the active ingredi-
ent. This technique has been utilized in the delivery of some antimicrobial agents for the
eradication of Helicobacter pylori (5).
At 5.0% (m/V) mucuna gum concentration, crosslinking did not reduce the release
rate of the drug, as the microspheres which were not crosslinked (MGF-0) had lower re-
lease than the crosslinked microspheres (Fig. 1a). This may be due to higher gelation in
the microspheres prepared without crosslinking, which possessed higher diffusional path
length, and the fact that the release of the drug from the crosslinked microspheres pro-
ceeded with disintegration of the matrix. However, at the crosslinking time of 3 h (MGF-
-3) the ultimate release was lower than that of the microspheres that were not crosslinked
(Fig. 1a). Their low release was not due to the low drug content as the batch had loading
efficiency of above 80%. It was due to strong attachment of the drug to the polymer ma-
trix. The same trend was observed in microspheres formulated with 7.5% (m/V) mucuna
gum (Fig. 1b). In Fig. 1c, it was observed that crosslinking affected the drug release, as
the microspheres that were not crosslinked had the fastest and highest release. These
microspheres were formulated with 10.0% (m/V) mucuna gum. The later burst effect (af-
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kH (% h–1/2) R2 kRP (h–1) n R2
MGF-0 20.763 0.6311 0.3919 0.0934 0.8486
MGF-1 29.081 0.8070 0.5833 0.1096 0.9233
MGF-3 11.666 0.8590 0.6825 0.1349 0.8781
MGF-5 23.244 0.9622 0.7511 0.1780 0.9339
MGS-0 6.330 0.9746 0.8368 0.1049 0.9850
MGS-1 39.149 0.9290 0.5857 0.3155 0.9271
MGS-3 12.898 0.9175 0.8136 0.1378 0.9297
MGS-5 49.960 0.8424 0.3699 1.5264 0.7274
MGT-0 24.547 0.4486 0.9057 0.3537 0.6855
MGT-1 59.113 0.5929 0.0483 1.0074 0.5197
MGT-3 22.160 0.9669 0.7549 0.1690 0.9225
MGT-5 52.254 0.8737 0.5047 0.8592 0.8240
Gelatin 44.078 0.9661 0.6286 0.3561 0.9635
kH – Higuchi release rate constant
kRP – Ritger-Peppas release rate constant
n – diffusional exponent
ter 2.5 h) observed with microspheres formulated with 10.0% (m/V) mucuna gum and
crosslinked for 1 h, which is depicted in Fig. 1c could be a result of insufficient time for
mutual migration and interaction of the crosslinking agent and the mucuna gum, since
the gum concentration was high.
Different mathematical models were used to describe the kinetics of glibenclamide
release from the microspheres. The criterion for selecting the most appropriate model
was chosen on the basis of a goodness-of-fit test. The release kinetics equation was ap-
plied to the whole release period because very few of the microspheres released 100% of
the included drug. The result of the different parameters derivable from the release mo-
dels is presented in Table II. The values show that with respect to Higuchi’s model (17),
MGF-5, MGS-0, MGS-1, MGS-3, MGT-3 and gelatin microspheres obeyed the model and
thus exhibited diffusion-controlled release. The implication is that at 5.0% (m/V) mu-
cuna gum concentration, crosslinking the microspheres for 5 h increased the diffusional
tendency of the incorporated drug. Similarly, at 7.5% (m/V) mucuna gum the micro-
spheres diffusionally released up to 3 h crosslinking. Only 3 h of crosslinking produced
microspheres that had Higuchi diffusional release in 10.0% (m/V) mucuna gum micro-
spheres (MGT-3). In the Ritger-Peppas model (18), all the microspheres formulated, ex-
cept MGS-5, MGT-1 and MGT-5, had n values lower than 0.43, and thus exhibited case I
Fickian diffusion. Case II transport dominated in MGS-5, MGT-1 and MGT-5 microspheres
(n ³ 0.85), indicating a predominantly zero-order release process. However, only MGF-1,
MGF-5, MGS-0, MGS-1, MGS-3, MGT-3 and gelatin microspheres could be said to have
had straight line plots (R2 ³ 0.9) (Table II), and thus followed the case I transport. These
batches may have maintained constant planar surface area for diffusion during the re-
lease process. Higher kRP values indicate higher release rates. As a result, crosslinked
microspheres at 5% (m/V) mucuna gum concentration had higher release rates than the
microspheres that were not crosslinked. Microspheres formulated with 7.5% (m/V) and
10% (m/V) mucuna gum without crosslinking (MGS-0 and MGT-0) had higher kRP val-
ues than the crosslinked microspheres, and thus had a higher release rate according to
this model. This result, although contrary to that obtained for 5.0% (m/V) mucuna gum
microspheres, may be due to higher polymer concentration and low crosslinker concen-
tration. The same quantity of crosslinking agent was used throughout. MGF-0, MGS-0
and MGT-0 possessed different release kinetics, which were different from the expected
trend because of the different polymer but constant drug concentration. Therefore, the
location of the drug within the polymer matrix affected the release kinetics.
The effect of crosslinking varied and appeared to be affected by polymer concentra-
tion (under constant stirring). Overall analysis of the release mechanism indicated that
of all the microspheres formulated, 54% of the total followed the Ritger-Peppas case I
transport model while 46% followed Higuchi’s diffusion model.
CONCLUSIONS
Microspheres with good in vitro properties were formulated with mucuna gum. In
vitro evaluation is expected to launch further research into the field of antidiabetic drug
delivery considering the functional properties of mucuna gum.
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S A @ E T A K
Mikrosfere s mukuna gumom za peroralnu primjenu
glibenklamida: In vitro ispitivanje
ANTHONY AMAECHI ATTAMA i OBICHUKWU J. NWABUNZE
U radu je opisana priprava mikrosfera s mukuna gumom za peroralnu primjenu gli-
benklamida. Pri izradi mikrosfera varirana je koncentracija polimera i vrijeme umre`a-
vanja, a brzina je bila konstantna. Mikrosfere su zatim punjene glibenklamidom metodom
odvojenog punjenja. Pripravljenim mikrosferama procijenjena je veli~ina ~estica, iskori-
{tenje, u~inkovitost punjenja i sposobnost bubrenja. In vitro osloba|anje glibenklamida
iz mikrosfera pra}eno je u simuliranoj intestinalnoj teku}ini (SIF, pH 7.4). Za odre|ivanje
mehanizma osloba|anja ispitana su dva modela. Sve mikrosfere su imale dobru sposob-
nost bubrenja u destiliranoj vodi. Optimalno produljeno osloba|anje glibenklamida pos-
tignuto je iz mikrosfera prire|enih s 5% (m/V) mukuna gume, uz vrijeme umre`avanja 5
h. Ljekovita tvar se najsporije osloba|ala iz mikrosfera prire|enih s 10% (m/V) mukuna
gume, uz vrijeme umre`avanja 1 h, dok se najbr`e osloba|ala iz mikrosfera s 10% (m/V)
gume, bez umre`avanja. Nekoliko mehanizama osloba|anja uklju~eno je u otpu{tanje
ljekovite tvari iz mikrosfera. Me|utim, Ritger-Peppasov transportni model I opisuje proces
osloba|anja u 54% slu~ajeva, {to zna~i da mikrosfere glibenklamida s mukuna gumom
predstavljaju pouzdan sustav za peroralnu primjenu te ljekovite tvari.
Klju~ne rije~i: mukuna guma, mikrosfere, glibenklamid, in vitro osloba|anje, peroralna primjena
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